

## Steps taken after granting the Marketing Authorisation

For procedures finalised after 1 October 2003 please refer to module 8B.

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                                                                                                                                                                                                                                           | Application number | Type of modification <sup>1</sup> | Notification/Opinion issued on <sup>2</sup> | Commission Decision Issued/amended on |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-----------------------------------|---------------------------------------------|---------------------------------------|
| Change in or addition of manufacturing site(s) for part or all of the manufacturing process                                                                                                                                                                                     | I/0001             | I                                 | 15.11.00                                    | -                                     |
| Change in supplier of an intermediate compound used in the manufacture of the active substance<br>Minor change of manufacturing process of the active substance<br>Change in specification of starting material or intermediate used in the manufacture of the active substance | I/0002             | I                                 | 04.12.00                                    | -                                     |
| Change in pack size for a medicinal product                                                                                                                                                                                                                                     | I/0003             | I                                 | 12.12.00                                    | 16.02.01                              |
| Change in or addition of manufacturer(s) of active substance.<br>Change in supplier of an intermediate compound used in manufacture of the active substance.<br>Minor change of manufacturing process of the active substance.<br>Change in test procedure of active substance. | I/0004             | I                                 | 06.04.01                                    | -                                     |
| Update of section 5.1 of the Summary of Product Characteristics                                                                                                                                                                                                                 | II/0005            | II                                | 13.12.01                                    | 12.04.02                              |
| Change of legal status with the consequent change in section 4.2 of the Summary of Product Characteristics                                                                                                                                                                      | II/0006            | II                                | 21.11.02                                    | 17.03.03                              |
| Change in or addition of manufacturer(s) of active substance<br>Minor change of manufacturing process of the active substance<br>Change in test procedure of active substance                                                                                                   | I/0007             | I                                 | 11.12.02                                    | -                                     |
| Increase of the maximum daily dose of pioglitazone to 45 mg                                                                                                                                                                                                                     | II/0008            | II                                | 22.05.03                                    | 28.08.03                              |
| Extension of indication for the use of pioglitazone as second line monotherapy                                                                                                                                                                                                  | II/0009            | II                                | 22.05.03                                    | 28.08.03                              |
| Additional strength: tablets of 45 mg                                                                                                                                                                                                                                           | X/0010             | X                                 | 26.06.03                                    | 16.09.03                              |

<sup>1</sup> In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: **I** refers to a minor variation (Type I variation); **II** refers to a major variation (Type II variation); **I/II** refers to a minor variation following the procedure set out in Article 6, 7 and 8 of the Regulation; **X** refers to an Annex II application.

**T** refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 of 7 November 1996.

**N** refers to a notification in accordance with Article 61(3) of Directive 2001/83/EC of 6 November 2001.

<sup>2</sup> For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification date. The Commission Decision will be amended accordingly.